We thus narrowed our investigational field to the thyroid cancer line FTC-133 after exposure to the three catalytic inhibitors, to deep inside the post-translational mechanism by which the IDO1 catalytic inhibitors increase the protein level in the tumor cells. The gene discussed is IDO1; the disease is thyroid gland carcinoma.